ERBB2 and gastric cancer: While revolutionary, its limitations include cardiotoxicity and resistance, addressed partly by biosimilars like Ogivri and Kanjinti, as biosimilars of trastuzumab, are used to treat HER2-positive breast and gastric cancers by inhibiting tumour growth [60].